ReviewClinical medicine (London, England)2017
Gout - a guide for the general and acute physicians.
Review in Clinical medicine (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 3 syntheses or guidelines pooled it, 106 citations in OpenAlex.
- Effect of tea intake on genetic predisposition to gout and uric acid: a Mendelian randomization study.Frontiers in endocrinology · 2023Pooled it
- Single-nucleotide polymorphisms link gout with health-related lifestyle factors in Korean cohorts.PloS one · 2023Pooled it
- Oral prednisolone versus non-steroidal anti-inflammatory drugs in the treatment of acute gout: a meta-analysis of randomized controlled trials.Inflammopharmacology · 2018Pooled it
- Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study.Arthritis research & therapy · 2025Trial
- Effects of febuxostat in different doses on uric acid, inflammatory factors of serum and knee articular cavity, endothelin-1, and oxidative stress in patients with a gout-a comparative study.African health sciences · 2024Trial
- Axial skeleton involvement in gout: clinical spectrum and dual-energy computed tomography findings from a descriptive real-world study.Clinical rheumatology · 2026Article
- In Silico Molecular Docking Studies and Xanthine Oxidase Inhibitory Activity ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Acetylshikonin alleviates gouty arthritis by increasing sirtuin1 expression and promoting lymphatic drainage.BMC pharmacology & toxicology · 2026Article
- The Progress of Gout Prediction Models Based on Multi-source Data.Current rheumatology reviews · 2026Review
- Serum uric acid and the incidence of new-onset metabolic syndrome among military young adults in Taiwan: the CHIEF cohort study.Frontiers in clinical diabetes and healthcare · 2026Article
- Severe tophaceous gout in the setting of myelofibrosis: A clinical challenge.Radiology case reports · 2026Article
- Neutrophil diversity and function in health and disease.Signal transduction and targeted therapy · 2024Review
- Resolution of acute inflammation induced by monosodium urate crystals (MSU) through neutrophil extracellular trap-MSU aggregate-mediated negative signaling.Journal of inflammation (London, England) · 2024Article
- Neonatal encephalopathy due to suspected hypoxic ischemic encephalopathy: pathophysiology, current, and emerging treatments.World journal of pediatrics : WJP · 2024Review
- Allopurinol is Associated with an Increased Risk of Cerebral Infarction: A Two-Sample Mendelian Randomization Study.ACS omega · 2024Article
- Review
- Article
- CD8 T cell-derived perforin regulates macrophage-mediated inflammation in a murine model of gout.Clinical rheumatology · 2024Article
- Network pharmacology identification andPharmaceutical biology · 2023Review
- Allopurinol versus Febuxostat: A New Approach for the Management of Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.Biomedicines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gout is the most prevalent inflammatory arthritis and affects 2.5% of the general population in the UK. It is also the only arthritis that has the potential to be cured with safe, inexpensive and well tolerated urate-lowering treatments, which reduce serum uric acid by either inhibiting xanthine oxidase - eg allopurinol, febuxostat - or by increasing the renal excretion of uric acid. Of these, xanthine oxidase inhibitors are used first line and are effective in 'curing' gout in the vast majority of patients. Gout can be diagnosed on clinical grounds in those with typical podagra. However, in those with involvement of other joints, joint aspiration is recommended to demonstrate monosodium urate crystals and exclude other causes of acute arthritis, such as septic arthritis. However, a clinical diagnosis of gout can be made if joint aspiration is not feasible. This review summarises the current understanding of the pathophysiology, clinical presentation, investigations and treatment of gout.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.